Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
Recruiting now
Conditions studied: Locally Advanced Hepatocellular Carcinoma, Liver Cirrhosis, Non-metastatic Hepatocellular Carcinoma
In brief
This study aims to evaluate the effectiveness and safety of Holmium-166 (Ho-166) transarterial radioembolization (TARE) for treating patients with locally advanced hepatocellular carcinoma (HCC), a common type of liver cancer. HCC is often linked to conditions like liver cirrhosis and viral hepatitis, with a poor prognosis for advanced stages. TARE involves delivering radioactive particles directly to liver tumors, sparing healthy tissue and providing targeted radiation. This study will include patients diagnosed with HCC who have received Holmium-166 TARE treatment between January 2010 and December 2024. Researchers will look at patient and tumor characteristics, side effects, how well the treatment works, and survival outcomes. The goal is to determine whether Holmium-166 TARE is a safe and effective treatment option for people with locally advanced HCC. The findings will help doctors better understand how this therapy can be used to treat liver cancer and whether it can improve survival rates for patients with this challenging disease.
Key facts
- Study ID
- NCT06873269
- Run by
- Universitair Ziekenhuis Brussel
- People needed
- 100
- Starts
- 2025-02-01
- Expected to finish
- 2026-02-01
- Last updated by the study team
- 2025-03-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- aged 18 year or older
- diagnosed with locally advanced HCC without extra-hepatic metastases
- HCC must not be amendable to treatment by surgical resection or percutaneous radiofrequency ablation
- after assessment by the investigator and multidisciplinary tumor board, the patient is considered suitable for protocol treatment with Holmium-166 TARE
- ECOG performance status 0-2
- child-Pugh A-B
- tumor response evaluable with mRECIST criteria during follow-up
You may not qualify if…
- prior treatment with any of the following treatment modalities for HCC: systemic therapy, hepatic radiation therapy
- currently enrolled in clinical studies where patient receive investigational therapeutic drug
- metastatic disease
- concurrent malignancy
- active contra-indications to angiography or selective catherization (i.e. severe vascular disease or bleeding diathesis)
- uncontrolled and/or severe comorbidities (active infection, heart failure,...) with limited estimated life expectancy
- history of or know allergic reactions to used compounds
Where it is running
- UZ Brussel — Brussels, Belgium (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.